72 related articles for article (PubMed ID: 22270106)
21. Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study.
Ishikawa M; Takashima A; Nagata Y; Sawada R; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Iwasa S; Okita N; Kato K; Saruta M; Boku N
PLoS One; 2021; 16(9):e0257551. PubMed ID: 34559818
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Nielsen DL; Palshof JA; Larsen FO; Jensen BV; Pfeiffer P
Cancer Treat Rev; 2014 Jul; 40(6):701-15. PubMed ID: 24731471
[TBL] [Abstract][Full Text] [Related]
23. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer.
Tonini G; Imperatori M; Vincenzi B; Frezza AM; Santini D
J Exp Clin Cancer Res; 2013 Nov; 32(1):92. PubMed ID: 24245912
[TBL] [Abstract][Full Text] [Related]
24. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
27. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
[TBL] [Abstract][Full Text] [Related]
28. Successful cetuximab therapy after failure of panitumumab rechallenge in a patient with metastatic colorectal cancer: restoration of drug sensitivity after anti-EGFR monoclonal antibody-free interval.
Hata A; Katakami N; Kitajima N
J Gastrointest Cancer; 2014 Dec; 45(4):506-7. PubMed ID: 24880984
[No Abstract] [Full Text] [Related]
29. Options for metastatic colorectal cancer beyond the second line of treatment.
Foubert F; Matysiak-Budnik T; Touchefeu Y
Dig Liver Dis; 2014 Feb; 46(2):105-12. PubMed ID: 23954144
[TBL] [Abstract][Full Text] [Related]
30. Report from the 37th san antonio breast cancer symposium, 9-13th december 2014, Texas, USA.
Ahmed M; Esposito E
Ecancermedicalscience; 2015; 9():508. PubMed ID: 25729421
[TBL] [Abstract][Full Text] [Related]
31. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Bodoky G; Scheulen ME; Rivera F; Jassem J; Carrato A; Moiseyenko V; Vynnychenko I; Prausová J; Van Laethem JL; Cascinu S; Ajani JA
J Gastrointest Cancer; 2015 Jun; 46(2):109-17. PubMed ID: 25707610
[TBL] [Abstract][Full Text] [Related]
32. High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.
Sakaguchi I; Motohara T; Saito F; Takaishi K; Fukumatsu Y; Tohya T; Shibata S; Mimori H; Tashiro H; Katabuchi H
J Gynecol Oncol; 2015 Jul; 26(3):193-200. PubMed ID: 25686399
[TBL] [Abstract][Full Text] [Related]
33. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Tabernero J; Chiorean EG; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD
Oncologist; 2015 Feb; 20(2):143-50. PubMed ID: 25582141
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
36. A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
Koizumi W; Morita S; Sakata Y
Jpn J Clin Oncol; 2015 Mar; 45(3):303-6. PubMed ID: 25516635
[TBL] [Abstract][Full Text] [Related]
37. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
[TBL] [Abstract][Full Text] [Related]
38. Ramucirumab: second-line therapy for gastric cancer.
Sasako M
Lancet Oncol; 2014 Oct; 15(11):1182-4. PubMed ID: 25240820
[No Abstract] [Full Text] [Related]
39. Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Chibaudel B; Tournigand C; Bonnetain F; Maindrault-Goebel F; Lledo G; André T; Larsen AK; Bengrine-Lefevre L; Louvet C; de Gramont A
Eur J Cancer; 2013 Dec; 49(18):3813-20. PubMed ID: 24011937
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini D; Vincenzi B; Addeo R; Garufi C; Masi G; Scartozzi M; Mancuso A; Frezza AM; Venditti O; Imperatori M; Schiavon G; Bronte G; Cicero G; Recine F; Maiello E; Cascinu S; Russo A; Falcone A; Tonini G
Ann Oncol; 2012 Sep; 23(9):2313-2318. PubMed ID: 22396447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
